What's Happening?
Biohub, a non-profit research organization co-founded by Priscilla Chan and Mark Zuckerberg, has released an updated version of its ESM protein language model family. This model, known as ESMC, is designed to enhance binder design and protein function
mapping for therapeutic discovery. The system includes ESMFold2, which translates evolutionary information into atomic-resolution protein structures and interactions. The model aims to transform drug discovery by making biology more programmable, potentially accelerating development timelines. ESMFold2 has demonstrated high-affinity protein binders against cancer and immunology targets, showing potential clinical utility. The models are accessible under the MIT license for both commercial and non-commercial use.
Why It's Important?
The release of Biohub's advanced protein biology model represents a significant step forward in the field of therapeutic discovery. By enabling more accurate digital representations of proteins, the model could streamline the drug discovery process, reducing the time and resources required to identify promising drug candidates. This advancement could lead to faster development of new therapies for diseases such as cancer and autoimmune disorders. The open-access nature of the model allows researchers worldwide to leverage its capabilities, fostering collaboration and innovation in the field of biotechnology. The initiative aligns with Biohub's commitment to advancing virtual biology and building predictive models of biology.
